5 April 2024 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the December 2023 PBAC ...
3 April 2024 - Bausch Health Canada today announced the first public drug plan listings for Uceris (budesonide) aerosol foam ...
4 April 2024 - Based on top-line results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started ...
1 April 2024 - CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in ...
3 April 2024 - The latest weight loss drugs are good. Really good. They can save lives and could literally remake ...
4 April 2024 - Application in moderate to severe hidradenitis suppurativa based on results from two Phase 3 studies where ...
2 April 2024 - Fanapt treatment is now available to adult patients for the acute treatment of manic or mixed episodes ...
3 April 2024 - Today, the US FDA approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with ...
2 April 2024 - RemeGen has obtained fast track designation by the US FDA recently for its innovative BLyS/APRIL dual-target ...
3 April 2024 - The agenda for the July 2024 PBAC meeting is now available. ...
2 April 2024 - Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, completion of the rolling submission of ...
3 April 2024 - NICE has published final evidence-based recommendations on the use of dostarlimab (Jemperli) in combination with platinum-based ...
2 April 2024 - Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled ...
2 April 2024 - Fast track designation for NOX-A12 follows recently announced FDA clearance of investigational new drug application for Phase ...
2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...